Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,501–7,600 of 15,747
Pirola, F. J. C., Santos, B. A. M., Sapienza, G. F., et al. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03592-4 · Cited by 9
“Several side effects have been reported in clinical trials following the use of different types of vaccines present on the market today [17, 18].”
BackgroundFerreira‐da‐Silva, R., Lobo, M. F., Pereira, A. M., Morato, M., Polónia, J. J., & Ribeiro‐Vaz, I. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1501921 · Cited by 17
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA VaccinationsPreprint
Bliden, K. P., Liu, T., Sreedhar, D., Kost, J., Hsiung, J., Zhao, S., Shan, D., Usman, A., Walia, N., Cho, A., et al. (2021) · medRxiv · doi:10.1101/2021.06.28.21259338 · Cited by 10
“Early data analysis from the phase III Pfizer and Moderna vaccine clinical trials demonstrated that the vaccines were more than 90% effective in preventing illness and reducing disease severity and hospitalizations 7,8 .”
MethodWhitaker, M. D., Elliott, J., Gerard-Ursin, I. C. G., Cooke, G., Donnelly, C. A., Ward, H., Elliott, P., & Chadeau‐Hyam, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)01912-9 · Cited by 16
Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization
Ragone, C., Mauriello, A., Cavalluzzo, B., Cavalcanti, E., Russo, L., Manolio, C., Mangano, S., Cembrola, B., Tagliamonte, M., & Buonaguro, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1398002 · Cited by 11
Current status of coronavirus disease 2019 vaccine research based on bibliometric analysis
Gan, P., Pan, X., Huang, S., Xia, H., Zhou, X., & Tang, X. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2119766 · Cited by 9
“The top co-cited reference, titled “Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,” was cited >1,000 times and was also the most cited article.(24) Most of the highly cited and co-cited articles focused on”
BackgroundAutoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios
Cairoli, E., & Espinosa, G. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.05.003 · Cited by 16
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01614-w · Cited by 33
Candon, S., Lemee, V., Lévêque, É., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.280139 · Cited by 9
“Sophie Candon,1,2 Véronique Lémée,3 Emilie Lévêque,4 Pascaline Etancelin,5 Cédric Paquin,5 Marion Carette,1 Nathalie Contentin,6 Victor Bobée,7 Mustafa Alani,6 Nathalie Cardinaël,6 Stéphane Leprêtre,6 Vincent Camus,6 Florian Bouclet,6 Edwige Boulet,8 Anne-Lise Ménard,6 Hélène Lanic,6 Aspasia Stamatoullas,6,9 Emilie Le…”
BackgroundInfluentialRuggeri, E. M., Nelli, F., Fabbri, A., Onorato, A., Giannarelli, D., Berrìos, J. R. G., Virtuoso, A., Marrucci, E., Mazzotta, M., Schirripa, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100350 · Cited by 10
Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV
Marchitto, L., Chatterjee, D., Ding, S., Gendron‐Lepage, G., Tauzin, A., Boutin, M., Benlarbi, M., Medjahed, H., Sylla, M., Lanctôt, H., et al. (2023) · Viruses · doi:10.3390/v15102004 · Cited by 9
Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over six months
(2021) · doi:10.1101/2021.09.13.21263535 · Cited by 9
“Prior COVID-19 was defined by a positive SARS-CoV-2 PCR test at any time before the date of full vaccination or SAb-IgG titer ≥1 U/L before or within 10 days after the first vaccine dose (representing likely prior undiagnosed COVID-19, as suggested by prior studies 2,26 ).”
Nakayama, E. E., & Shioda, T. (2024) · Pathogens · doi:10.3390/pathogens13121109 · Cited by 9
“…context of COVID-19, there are two main types of vaccine against SARS-CoV-2: (1) those targeting only the S protein, including mRNA-based vaccines [101–103], adenovirus vector vaccines [104], and recombinant protein vaccines [105]; and (2) those targeting the whole virion, which includes the N…”
Wang, Z., Liu, X., Jin, J., Liu, X., Liu, C., Xie, F., Wang, X., An, F., Xiao, B., Cheng, H., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202420308 · Cited by 16
Cohen‐Dvashi, H., Weinstein, J. J., Katz, M., Eilon-Ashkenazy, M., Mor, Y., Shimon, A., Achdout, H., Tamir, H., Israely, T., Strobelt, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105193 · Cited by 9
Sammartino, J. C., Cassaniti, I., Ferrari, A., Giardina, F., Ferrari, G., Zavaglio, F., Paolucci, S., Lilleri, D., Piralla, A., Baldanti, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10050703 · Cited by 9
“BNT162b2 is a novel RNA-based vaccine encoding the full-length SARS-CoV-2 Spike protein, with a 95% protection rate against COVID-19, approved for emergency use by the WHO in December 2020, only 11 months after its development started [4].”
BackgroundSakamoto, A., Yoshimura, M., Itoh, R., Ozuru, R., Ishii, K., Sechi, Y., Nabeshima, S., & Hiromatsu, K. (2022) · Vaccines · doi:10.3390/vaccines10060830 · Cited by 9
Cérda, S. L., Molinaro, G., Tello, R. P., Correia, A., Waris, E., Hirvonen, J. J., Barreto, G., & Santos, H. A. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c02996 · Cited by 11
Favre, D., Harmon, J. F., Zhang, A., Miller, M. S., & Kaltashov, I. A. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2022.111899 · Cited by 12
Chang, Y., Chen, Y., Yang, C., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70202 · Cited by 9
Ouldali, N., Bagheri, H., Salvo, F., Antona, D., Pariente, A., Leblanc, C., Tebacher, M., Micallef, J., Lévy, C., Cohen, R., et al. (2022) · medRxiv · doi:10.1101/2022.01.17.22269263 · Cited by 9
Soldatov, A. A., Kryuchkov, N. A., Витальевич, Г. Д., Авдеева, Ж. И., Свитич, О. А., & Soshnikov, S. S. (2025) · Vaccines · doi:10.3390/vaccines13080789 · Cited by 13
“Although COVID-19 vaccines can induce high titers of neutralizing IgG and IgA class antibodies against the SARS-CoV-2 spike protein, they only offer temporary protection against the SARS-CoV-2 infection [1,111–113].”
A Comprehensive Analysis of Biopharmaceutical Products Listed in the FDA’s Purple Book
Chen, F., Zhong, H., Chan, G., & Ouyang, D. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02802-0 · Cited by 12
“Notably, in 2021, COVID-19 vaccine mRNA (Comirnaty ® ) received approval to prevent COVID-19 infection [16], marking a noteworthy accomplishment in the aftermath of the pandemic.”
Duarte, G. G., Coutinho, C. M., Rolnik, D. L., Quintana, S. M., Silva, A. C. R. E., Poon, L. C., & Costa, F. D. S. (2021) · AJOG Global Reports · doi:10.1016/j.xagr.2021.100020 · Cited by 12
“This vaccine has a high effectiveness rate of 95%.(5) However, a low tempera-”
BackgroundDonhauser, L. V., de Oliveira, J. V., Schick, C., Manlik, W., Stýblová, S., Lutzenberger, S., Aigner, M., Philipp, P., Robert, S., Gandorfer, B., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007387 · Cited by 9
Hassan, A., Prasad, D., Rani, S., & Alhassan, M. (2022) · BioMed Research International · doi:10.1155/2022/7731618 · Cited by 5
“However, despite such an unprecedented collaboration on the development and deployment of vaccines, COVID19 pandemic is still far from over [28].”
BackgroundRetractedSousa, M. J., Caramujo, C., Júlio, N., Magalhães, J. C., Basto, R., Fraga, T., Gomes, I. F., Monteiro, A. R., Pazos, I., & Sousa, G. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06886-x · Cited by 10
Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence
Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 10
“The related academic article [33] reported 6 severe cases between 14 and 112 days after receiving vaccine or placebo, of whom 1 was in the vaccine group. e Protocols for defining asymptomatic infection varied across the countries in the ChAdOx1-S trial, which limits the reliability of these point…”
BackgroundPossas, C. D. A., Antunes, A. M. D. S., de Oliveira, A. M., Mendes, C. D. D. S., Ramos, M. P., Schumacher, S. D. O. R., & Homma, A. (2021) · Circular Economy and Sustainability · doi:10.1007/s43615-021-00051-y · Cited by 10
Alamer, A., Almulhim, A., Alrashed, A. A., et al. (2021) · Healthcare · doi:10.3390/healthcare9020127 · Cited by 9
Frequent Onsets of Cellulitis in Lower Limbs with Lymphedema Following COVID-19 mRNA Vaccination
Okazaki, T., Matashiro, M., Kodama, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10040517 · Cited by 9
Okada, S., Tomita, K., Inui, G., Ikeuchi, T., Touge, H., Hasegawa, J., & Yamasaki, A. (2022) · Yonago acta medica · doi:10.33160/yam.2022.02.012 · Cited by 11
Doxofylline Protects Gram-Negative Pathogens against Antibiotic-Mediated Killing
Chen, H., Yang, N., Yang, Y., Zheng, Y., Xu, M., Zhang, H., Liu, Y., Shen, W., & Li, J. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00417 · Cited by 10
Reactogenicity to COVID-19 vaccination in the United States of America
Sanyaolu, A. O., Marinkovic, A., Prakash, S., Desai, P., Haider, N., Abbasi, A. F., Mehraban, N., Jain, I., Ekeh, A., Shazley, O., et al. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.1.104 · Cited by 9
“The phase 3 clinical trial that was conducted to determine the efficacy of the Pfizer-BioNTech vaccine randomized 43,448 volunteers to receive either the vaccine or a placebo [2].”
BackgroundInfluentialTrümpelmann, S., Schulte‐Mecklenbeck, A., Steinberg, O. V., Wirth, T., Fobker, M., Lohmann, L., Lünemann, J. D., Wiendl, H., Groß, C. C., & Klotz, L. (2022) · Clinical and Translational Science · doi:10.1111/cts.13256 · Cited by 7
Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis
Zhang, X., Guo, M., Huang, Z., Huang, Y., Wu, C., & Pan, X. (2022) · Infectious Medicine · doi:10.1016/j.imj.2022.06.005 · Cited by 10
Kwon, R., & Rahmati, M. (2022) · Life Cycle · doi:10.54724/lc.2022.e15 · Cited by 9
Yang, X., Zhang, J., Olatosi, B., Weissman, S., & Li, X. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067095 · Cited by 9
“Based on WHO criteria, 30 we will place the breakthrough infections into strata: ‘mild’ (outpatient, WHO severity 1–3), ‘moderate’ (hospitalised without invasive ventilation, WHO severity 4–6), ‘severe’ (hospitalised with invasive ventilation or extracorporeal membrane oxygenation (ECMO), WHO…”
Role of Nanomaterials in COVID-19 Prevention, Diagnostics, Therapeutics, and Vaccine Development
Patel, U., Rathnayake, K., Hunt, E. C., & Singh, N. (2022) · Journal of Nanotheranostics · doi:10.3390/jnt3040011 · Cited by 9
“Due to their good sensitivity and affordability, nanoparticle-based assays have been suggested for the detection of SARSCoV-2 [33].”
BackgroundBajpai, J., Kant, S., Verma, A. K., Patwa, A. K., Atam, V., Chaudhary, S. C., & Pandey, A. K. (2022) · Cureus · doi:10.7759/cureus.25378 · Cited by 18
“This is not alarming, given that both vaccination brands approved in India have already shown remarkable efficacy in randomized controlled trials [12,13].”
BackgroundMartínez‐Fleta, P., Vicente‐Rabaneda, E. F., Triguero‐Martínez, A., Roy‐Vallejo, E., Uriarte-Ecenarro, M., Gutiérrez-Rodríguez, F., Quiroga-Colina, P., Romero-Robles, A., Montes, N. G., García-Castañeda, N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00805-3 · Cited by 10
Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection
Zhang, Q., Pavlinov, I., Ye, Y., & Zheng, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1364657 · Cited by 11
Sokhangouy, S. K., Behzadi, M., Rezaei, S., Farjami, M., Haghshenas, M., Sefidbakht, Y., & Mozaffari‐Jovin, S. (2025) · Biotechnology Journal · doi:10.1002/biot.202400596 · Cited by 12
“The COVID-19 pandemic led to the rapid development of vaccines, with mRNA-based vaccines, including mRNA-1273 and BNT162b2, becoming widely administered due to their high efficacy against the virus [4, 5].”
A review of neuro-ophthalmic sequelae following COVID-19 infection and vaccination
Shi, J., & Danesh-Meyer, H. V. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1345683 · Cited by 15
Development of synthetic antigen vaccines for COVID-19
Invenção, M. D. C. V., Melo, A. R. D. S., de Macêdo, L. S., Neves, T. S. P. D. C., de Melo, C. M. L., Cordeiro, M. N., Batista, M. V. D. A., & de Freitas, A. C. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1974288 · Cited by 10
Ashhurst, A. S., Tang, A. H., Fajtová, P., Yoon, M. C., Aggarwal, A., Stoye, A., Larance, M., Beretta, L., Drelich, A. K., Skinner, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.23.424111 · Cited by 9
Bilateral Panuveitis with Occlusive Vasculitis following Coronavirus Disease 2019 Vaccination
Hébert, M., Couture, S., & Schmit, I. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2042325 · Cited by 9
Uprichard, S. L., O’Brien, A., Evdokimova, M., Rowe, C. L., Joyce, C., Hackbart, M., Cruz-Pulido, Y. E., Cohen, C. A., Rock, M. L., Dye, J. M., et al. (2022) · Viruses · doi:10.3390/v14020370 · Cited by 10
“In agreement with recent reports [32,33], we saw no overall differences in vaccine antibody response between males and females (p = 0.”
BackgroundResultChang-Rabley, E., van Zelm, M. C., Ricotta, E., & Edwards, E. S. J. (2024) · Vaccines · doi:10.3390/vaccines12060675 · Cited by 12
“…or mild respiratory disease including fever, cough, and lethargy, a subset of individuals mount an inappropriately strong inflammatory response to high viral loads, resulting in severe illness, hospitalization, respiratory support, Vaccines 2024 , 12 , 675 2 of 32 and in some cases death [9,10].”
BackgroundSafety and immunogenicity of mRNA COVID ‐19 vaccine in inpatients with muscular dystrophy
Saito, T., Saito, T., Hashimoto, H., Ogata, K., Kobayashi, M., Takada, H., Kuru, S., Kimura, T., Nakamura, A., & Matsumura, T. (2022) · Muscle & Nerve · doi:10.1002/mus.27761 · Cited by 7
Worldwide epidemiology of neuro-coronavirus disease in children: lessons for the next pandemic
Alcamo, A. M., McGuire, J. L., Kanthimathinathan, H. K., Roa, J. D., & Fink, E. L. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001069 · Cited by 9
“In addition, while there was early concern of acute onset peripheral facial nerve palsy following mRNA-based vaccine administration (Pfizer-BioNTech, Moderna) [95,96], subsequent evaluation of 320 million vaccination administrations from the WHO database demonstrated no increase over baseline population incidence foll…”
BackgroundTawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Vanichsetakul, P., Thonginnetra, S., Niemsorn, K., Promsena, P., Tandhansakul, M., Kasemlawan, N., Ruangkijpaisal, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10050807 · Cited by 8
Namazova-Baranova, L. S., Fedoseenko, М. V., Shakhtakhtinskaya, F. C., Kaliuzhnaia, T. A., Soloshenko, M. А., Васильевна, Т. С., Месроповна, С. А., Privalova, T. E., Дмитриевна, Т. С., Melnikova, A. A., et al. (2022) · Вопросы современной педиатрии · doi:10.15690/vsp.v21i2.2386 · Cited by 9
COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies
Harris, C. E., Vijenthira, A., Ong, S. Y., Baden, L. R., Hicks, L. K., & Baird, J. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390778 · Cited by 11
Flaxman, A. D., Issema, R. S., Barnabas, R. V., & Ross, J. M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8632 · Cited by 11
Avoidance of COVID-19 for Children and Adolescents and Isolation Precautions
Gupta, S., Smith, L., & Diakiw, A. (2021) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2021.05.011 · Cited by 10
Bardenheier, B. H., White, E. M., Blackman, C., Gravenstein, S., Gutman, R., Sarkar, I. N., Feifer, R. A., McConeghy, K. W., Nanda, A., Duprey, M. S., et al. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17812 · Cited by 8
“This research supports previous reports from the original randomized trials of these vaccines that did not include nursing home residents.(12,13) Furthermore, the mRNA-based booster dose offers the potential of being life-saving for nursing home residents who have borne a disproportionate share of morbidity and mortal…”
ResultJaishwal, P., Jha, K., & Singh, S. P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134012 · Cited by 12
Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
Mahrokhian, S. H., Tostanoski, L. H., Jacob-Dolan, C., Zahn, R. C., Wegmann, F., McMahan, K., Yu, J., Gebre, M. S., Bondzie, E. A., Wan, H., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00454-4 · Cited by 11
SARS-CoV-2 and Its Variants: The Pandemic of Unvaccinated
Angius, F., Pala, G., & Manzin, A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.749634 · Cited by 10
Risk of Adverse Events and Delirium after COVID-19 Vaccination in Patients Living with Dementia
Cheung, E. C. L., Leung, M. T. Y., Chen, K., Wan, E. Y. F., Li, X., Lai, F. T. T., Wong, C. K. H., Qin, X. S., Chan, E. W., Lau, K. K., et al. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.04.003 · Cited by 9
Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model
England, R. N., Drapeau, E. M., Alameh, M., Hosseinzadeh, R., Weissman, D., & Hensley, S. E. (2024) · npj Vaccines · doi:10.1038/s41541-024-00901-4 · Cited by 11
Tuning hydrogen bonds and electrostatics with convection for purifying mRNA: A paradigm shift
Neuman, T. G., Banik, R., Karla, S., Hu, M., Hartin, A., Karande, P., Kilduff, J. E., & Belfort, G. (2025) · Science Advances · doi:10.1126/sciadv.adv8656 · Cited by 9
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic
Chen, P., Shi, X., He, W., Zhong, G., Tang, Y., Wang, H., & Zhang, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2040330 · Cited by 10
“were over 55 years of age, suggesting that the vaccine is also highly effective in elder individuals.(17) The phase III trial of mRNA-1237 also encounter similar result.”
BackgroundResultInfluentialZhang, X., Han, P., Wang, H., Xu, Y., Li, F., Li, M., Fan, L., Zhang, H., Dai, Q., Lin, H., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.004 · Cited by 9
Díaz, N. A., Buckley, R. D. M., Agüero, F., Sued, O. G., Arribas, J. R., Ambrosioni, J., Ambrosioni, J., Blanco, J. L., de la Mora, L., García, F., et al. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00547-y · Cited by 8
COVID-19’s natural course among ambulatory monitored outpatients
Weinbergerová, B., Mayer, J., Hrabovský, Š., Nováková, Z., Pospíšil, Z., Martykanova, L., Hortova, K., Mandelova, L., Hejduk, K., Chloupková, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89545-1 · Cited by 10
Matar, R., Mansour, R., Nakanishi, H., Smayra, K., Haddad, J. E., Vankayalapati, D. K., Daniel, R. S., Tosovic, D., Than, C. A., & Yamani, M. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154521 · Cited by 11
“Given that two doses of the mRNA vaccines are required to elicit adequate neutralizing antibody titers and antigen specific responses [105,106], the suggested pathophysiological mechanism may explain the increased frequency of myocarditis following vaccination with the second dose, as seen in 155 of 188 patients in th…”
ResultAltincekic, N., Jores, N., Löhr, F., Richter, C. P., Ehrhardt, C., Blommers, M. J. J., Berg, H., Öztürk, S., Gande, S. L., Linhard, V. L., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00720 · Cited by 9
Frank, A., Radparvar, S., Manasia, A. R., Bassily‐Marcus, A., & Kohli-Seth, R. D. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000397 · Cited by 9
Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction
Lamberti, A., Lora, V., Graceffa, D., Bonifati, C., & Cota, C. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18255 · Cited by 9
Stellini, R., Gianello, R., & Gomarasca, W. (2022) · Infection · doi:10.1007/s15010-022-01816-9 · Cited by 8
“A two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was demonstrated to be highly effective in preventing symptomatic COVID-19, both in clinical trials [1] and real-world settings [2].”
Levintow, S. N., DiRosa, E. A., Carda-Auten, J., et al. (2022) · American Journal of Public Health · doi:10.2105/ajph.2022.307012 · Cited by 9
COVID‐19 post‐vaccination lymphadenopathy: A review of the use of fine needle aspiration cytology
Caputo, A., Caleo, A., Cozzolino, I., Zeppa, P., Ciancia, G., & Ciliberti, V. (2023) · Cytopathology · doi:10.1111/cyt.13221 · Cited by 9
Shoji, K., Tsuzuki, S., Akiyama, T., Matsunaga, N., Asai, Y., Suzuki, S., Iwamoto, N., Funaki, T., Yamada, M., Ozawa, N., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.09.005 · Cited by 14
Tabll, A. A., Sohrab, S. S., Ali, A. A., Petrovic, A., Srdarević, S. S., Siber, S., Glasnović, M., Smolić, R., & Smolić, M. (2023) · Pathogens · doi:10.3390/pathogens13010038 · Cited by 10
Enayatrad, M., Mahdavi, S., Aliyari, R., Negah, S. S., Nili, S., Fereidouni, M., Shahrbabaki, P. M., Ansari‐Moghaddam, A., Heidarzadeh, A., Shahraki‐Sanavi, F., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08103-4 · Cited by 11
“Background The COVID-19 pandemic has caused significant mortality and morbidity worldwide, and until now, vaccination has been the most effective and promising strategy to control the spread of this disease [1, 2].”
BackgroundQin, K., Honjo, K., Sherrill-Mix, S. A., Liu, W., Stoltz, R., Oman, A. K., Hall, L., Li, R., Sterrett, S., Frederick, E. R., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004157 · Cited by 12
The effect of COVID-19 vaccines on sperm parameters: a systematic review and meta-analysis
Ma, Y., Cheng, C., Chi, Y., et al. (2022) · Asian Journal of Andrology · doi:10.4103/aja2022100 · Cited by 11
Hoepler, W., Weidner, L., Traugott, M. T., Neuhold, S., Meyer, E. L., Zoufaly, A., Seitz, T., Kitzberger, R., Baumgartner, S., Pawelka, E., et al. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1940271 · Cited by 9
Farhat, M., Al-Ibrahim, R., Almohammedali, A., Aljishi, R., & Alalwan, B. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s379204 · Cited by 11
SARS-CoV-2: The Virus, Its Biology and COVID-19 Disease-Counteracting Possibilities
Marschalek, R. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810273 · Cited by 10
“S) and ended with successful clinical trials [47–50].”
BackgroundBruun, T. U. J., Do, J., Weidenbacher, P. A. B., Utz, A., & Kim, P. S. (2024) · ACS Central Science · doi:10.1021/acscentsci.4c00722 · Cited by 9
Hagenbeck, C., Zöllkau, J., Helbig, M., Fehm, T. N., & Schaal, N. K. (2023) · Vaccines · doi:10.3390/vaccines11030627 · Cited by 13
“The main reasons against vaccination were fear of complications during pregnancy/breastfeeding and fear of harm to the unborn/newborn, which is also consistent with the results of other studies [3,19].”
BackgroundResultComparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety
Luo, C., Du, J., Cuker, A. C., Lautenbach, E., Asch, D. A., Poland, G. A., Tao, C., & Chen, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-13809-7 · Cited by 12
(2021) · doi:10.1101/2021.10.03.21264451 · Cited by 9
“The adverse events in various settings as well as rare adverse events are unknown.(1-4) Most resource-limited settings had limited access to vaccines in early 2021.”
BackgroundHe, Y.-R., Xia, H., Yun, P., Xu, Y., Ma, W. M. J., Xiao, Z.-X., & Zha, G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070940 · Cited by 10
Trunfio, M., Verga, F., Ghisetti, V., Burdino, E., Emanuele, T., Bonora, S., Perri, G. D., & Calcagno, A. (2021) · Vaccines · doi:10.3390/vaccines9121377 · Cited by 12
“As for post-vaccine symptomatic infections, the placebo-controlled phase III efficacy trial reported that no more than 10% of severe COVID-19 cases with onset after the first dose occurred in BNT162b2 recipients [1].”
BackgroundMolecular basis of Ad5-nCoV vaccine-induced immunogenicity
Dong, D., Song, Y., Wu, S., Wang, B., Peng, C., Zhang, W., Kong, W., Zhang, Z., Song, J., Hou, L., et al. (2025) · Structure · doi:10.1016/j.str.2025.02.009 · Cited by 8
Louapre, C., Belin, L., Marot, S., Hippolyte, A., Januel, É., Ibrahim, M., Jeantin, L., Zafilaza, K., Malet, I., Charbonnier‐Beaupel, F., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15925 · Cited by 8
Shi, Y., Guo, M., Yang, W., Liu, S., Zhu, B., Yang, L., Yang, C., & Liu, C. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1911653 · Cited by 9
Risk management and communication plans from SARS to COVID‐19 and beyond
Recchia, V., Aloisi, A., & Zizza, A. (2022) · The International Journal of Health Planning and Management · doi:10.1002/hpm.3545 · Cited by 10
Effectiveness of mRNA COVID-19 Vaccines in Adolescents Over 6 Months
Amodio, E., Genovese, D., Mazzeo, L., Martino, L., Restivo, V., Vella, G., Calamusa, G., & Vitale, F. M. (2022) · PEDIATRICS · doi:10.1542/peds.2022-057394 · Cited by 9
Eder, P., Łodyga, M., Dobrowolska, A., Reguła, J., & Rydzewska, G. M. (2021) · Gastroenterology Review · doi:10.5114/pg.2021.103666 · Cited by 9
Geisler, A., Dieringer, B., Elsner, L., Klingel, K., Klopfleisch, R., Vornlocher, H., Kurreck, J., & Fechner, H. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.016 · Cited by 9
“Adenoviral target sequence for siPol-1 (30-50)”
BackgroundOrfanoudaki, E., Zacharopoulou, E., Kitsou, V., Κarmiris, K., Theodoropoulou, A., Mantzaris, G. J., Tzouvala, M., Michopoulos, S., Zampeli, E., Michalopoulos, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030641 · Cited by 8
Egia‐Mendikute, L., Bosch, A., Prieto‐Fernández, E., Vila-Vecilla, L., Zanetti, S. R., Lee, S. Y., Jiménez-Lasheras, B., Río, A. G.-D., Antoñana-Vildosola, A., de Blas, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1014309 · Cited by 10
In vivo gene delivery to immune cells
Siebart, J. C., Chan, C. S., Yao, X., Su, F., & Kwong, G. A. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103169 · Cited by 12
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.